Compare iShares Russell 2000 ETF (IWM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Neurocrine Biosciences Inc — how do they compare? iShares Russell 2000 ETF trades at $278.54 (market cap $77.70B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: iShares Russell 2000 ETF is far larger — about 5.4× Neurocrine Biosciences Inc's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IWM | NBIX | |
|---|---|---|
Market Cap | $77.70B | $14.36B |
Volume | 35,598,983 | 1,237,180 |
52-Week High | $305.06 | $185.50 |
52-Week Low | $229.13 | $123.10 |
Typical Hold Time | 83 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.72, down 1.27% amid broader small-cap weakness. Technical indicators show a bearish trend with resistance at $278 and support at $275. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.
The outlook remains cautious as rising interest rates pressure small-cap valuations. Opportunities exist for long-term investors seeking diversification from tech-heavy large caps, but near-term risks include economic sensitivity and narrow market breadth. The bearish technical setup suggests further downside potential unless macroeconomic conditions improve.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
